Lucid Diagnostics (NASDAQ:LUCD), a commercial-stage medical diagnostics company focused on the early detection of esophageal precancer, today reported financial and operational results for the fourth quarter and full year ended December 31, 2025.
The company’s performance was highlighted by a significant expansion of its federal market access and the continued commercial scaling of its flagship EsoGuard Esophageal DNA Test.
Lucid reported fourth-quarter EsoGuard revenue of $1.5 million, derived from 3,664 tests performed during the period.
This contributed to a full-year 2025 revenue total of $4.706 million.
The growth in testing volume reflects broader clinical adoption across the company’s "CheckUp" events and satellite lounge network.
On the bottom line, Lucid reported a GAAP net loss of $16.3 million, or $0.12 per share, for the fourth quarter.
On a non-GAAP basis, the adjusted net loss was $12.6 million, as the company continues to invest in its specialized sales force and clinical evidence programs.
A primary catalyst for the company’s 2026 outlook is the recently secured national contract with the U.S. Department of Veterans Affairs (VA).
This agreement covers approximately 170 VA medical centers nationwide, providing veterans with access to EsoGuard testing at a Medicare-aligned price of $1,938 per test.
This contract represents a major opening into the single largest integrated healthcare system in the United States, targeting a patient population with a high prevalence of risk factors for esophageal adenocarcinoma.
Operational data released alongside the financial results further validated the clinical utility of the EsoCheck cell collection device.
Real-world evidence showed a 95% technical success rate, with 95% of procedures completed in under two minutes.
Financially, Lucid ended the year with $34.7 million in cash and cash equivalents.
Management noted that the current balance sheet, combined with the expected revenue acceleration from the VA contract and continued private payer engagement, provides the necessary resources to execute its commercial strategy through 2026.